Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

A Patient with Locally Advanced Pancreatic Cancer Who Refused Additional Chemotherapy

추가 항암 치료를 거부하는 국소 진행형 췌장암 환자 1례

  • Hee Seung Lee (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Moon Jae Chung (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Jeong Youp Park (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Seungmin Bang (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Seung Woo Park (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Si Young Song (Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine)
  • 이희승 (연세대학교 의과대학 세브란스병원 소화기내과) ;
  • 정문재 (연세대학교 의과대학 세브란스병원 소화기내과) ;
  • 박정엽 (연세대학교 의과대학 세브란스병원 소화기내과) ;
  • 방승민 (연세대학교 의과대학 세브란스병원 소화기내과) ;
  • 박승우 (연세대학교 의과대학 세브란스병원 소화기내과) ;
  • 송시영 (연세대학교 의과대학 세브란스병원 소화기내과)
  • Received : 2016.06.15
  • Accepted : 2016.12.23
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The prognosis for pancreatic cancer patient is very poor. Patients with locally advanced disease have a median survival time of 8 to 12 months, and patients with distant metastases have significantly worse outcomes, with a median survival time of only 3 to 6 months. Approximately 30% of patients with pancreatic cancer present with locally advanced disease defined as unresectable pancreatic cancer without evidence of distant metastatic disease. Primary treatment options in locally advanced pancreatic cancer include chemotherapy and radiotherapy. Here, we reported a patient with locally advanced pancreatic cancer who does not want further chemotherapy because of chemotherapy induced nausea and vomiting. Irreversible electroporation was performed. Irreversible electroporation was well tolerated in this case, and may be a therapeutic modality for selected patients with locally advanced pancreatic cancer.

Keywords

References

  1. Center NC. National cancer registration program. Goyang, Korea 2012.
  2. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014;371:1039-1049.
  3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
  4. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;33:1770-1778.
  5. Martin RC. Irreversible electroporation of locally advanced pancreatic head adenocarcinoma. J Gastrointest Surg 2013;17:1850-1856.
  6. Dunki-Jacobs EM, Philips P, Martin RCG. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. Journal of the American College of Surgeons 2014;218:179-187.
  7. Narayanan G, Hosein PJ, Arora G, et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012;23:1613-1621.
  8. Martin RC, 2nd, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015;262:486-494; discussion 492-484.